Stock comparison
Cytek Biosciences
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CTKB
Cytek Biosciences
Market cap
$517.86M
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CTKB | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 72B | LLY |
| Benjamin Graham | 35D | 86A | LLY |
| Philip Fisher | 30F | 86A | LLY |
| Peter Lynch | 22F | 74B | LLY |
| Joel Greenblatt | 0F | 78C | LLY |
| Charlie Munger | 21F | 85A | LLY |
| Terry Smith | 23F | 77C | LLY |
Side-by-side metrics
| Metric | CTKB | LLY |
|---|---|---|
| Market cap | $517.86M | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | - | 34.1x |
| ROIC (TTM) | -11.42% | 32.06% |
| Gross margin | 51.7% | 83.51% |
| Net margin | -36.25% | 34.98% |
| Revenue CAGR 5y | 12.02% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 0.1x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTKB leads on
- EV/EBIT-vs 34.1x+136%
- P/E (TTM)-vs 36.6x+119%
- Debt / Equity0.1xvs 1.4x+92%
LLY leads on
- Net margin34.98%vs -36.25%+197%
- ROIC (TTM)32.06%vs -11.42%+136%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $517.86M+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.